ASX-Dividend-Report-Banner

First Subject Enrolled in Phase 1 Study of MRX-5

November 20, 2023 09:34 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 First Subject Enrolled in Phase 1 Study of MRX-5
Image source: Kalkine Media

SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. (hereinafter referred to as "MicuRx") announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial in Australia.

MRX-5 is a new type of benzodiazepine antibiotic used to treat infections caused by NTMs (non-tuberculous mycobacteria). Non-tuberculosis mycobacteria refers to a large class of bacteria, excluding Mycobacteria tuberculosis, which causes chronic lung infections and results in lung damage and high mortality rates.  At least 250,000 people worldwide are actively being treated for NTM infections and incidence is increasing globally.

To date, more than 190 NTM species and 14 subspecies have been identified, with the most common pathogenic NTMs including the Mycobacterium abscess and the Mycobacterium avium complex. NTM infections require 12-24 months of antibiotic therapy taken multiple times per day.  Current treatments result in a high number of adverse reactions, inadequate clinical resolution, poor compliance and poor prognosis. Treatment of NTM patients, especially resistant patients, has significant unmet needs. New antibiotics which have greater efficacy, fewer adverse events and better patient compliance are urgently needed.

MicuRx is developing MRX-5 for treatment of refractory NTM infections.  Pre-clinical studies have shown that MRX-5 has good antibacterial activity for most common NTM bacteria and good safety in animal toxicology studies.

This Phase 1 study, the first human clinical trial of MRX-5, is conducted at the Nucleus Network Research Centre in Australia to assess the safety, tolerance, pharmacodynamic characteristics and food effects of oral MRX-5 in healthy subjects. The trial has previously been approved by the Australian Ethics Commission for Human Research (HREC) and has completed the clinical trial filing at the Therapeutic Goods Administration (TGA).  Completion is expected in 2024.

MicuRx is committed to advancing our pipeline products to serve the infectious disease and critical care markets where more therapeutic options are needed to address unmet medical needs.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.